Methotrexate (MTX), used as a graft-versus-host disease (GvHD) prophylactic agent in hematopoietic stem cell transplantation (HSCT), exerts its effect via folate cycle inhibition. A critical enzyme involved in folate metabolism is 5,10-methylenetetrahydrofolate reductase (MTHFR). We examined the association of a single nucleotide polymorphism (SNP) at position 677 in the MTHFR gene on GvHD outcomes in allogeneic HSCT patients administered MTX. MTHFR genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) on 193 HSCT patients and donors. A total of 140 patients were transplanted with an HLA-matched related donor and 53 with an unrelated donor. GvHD outcomes were compared between genotypes by univariate and multivariate analysis. The combined donor 677CT and TT genotypes were associated with a decreased incidence of GvHD (acute and chronic combined) in HSCT recipients with an HLA-matched related donor (75% at 1 year in the CT and TT group compared with 91% in the wild type CC group, P ¼ 0.01), increased time to onset of first GvHD (P ¼ 0.001) and time to first GvHD treated with systemic therapy (P ¼ 0.022). Unrelated donor MTHFR genotype was not associated with outcome parameters and no associations of recipient genotype in either related or unrelated donor cohorts were observed.
Introduction
Methotrexate (MTX) is commonly administered to allogeneic hematopoietic stem cell transplant (HSCT) recipients as graft-versus-host disease (GvHD) prophylaxis 1 usually in association with other immunosuppressive agents. Methotrexate inhibits GvHD by preventing activated, mature donor T lymphocytes from expanding and induces apoptosis. 2 Methotrexate competes with intracellular folate for binding to the enzyme dihydrofolate reductase (DHFR), which results in depletion of folate substrates such as tetrahydrofolate and 5,10-methylenetetrahydrofolate. These folate substrates are carbon group donors for the synthesis of pyrimidines and purines, nucleotides required for DNA and RNA synthesis and also for DNA methylation. 2, 3 The enzyme 5,10-methylenetetrahydrofolate, reductase (MTHFR), which catalyzes the reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate is critical in apportioning folate substrates to downstream nucleotide synthesis and DNA methylation. 4 As sufficient de novo nucleotide biosynthesis is required for T-lymphocyte cell growth, 5 MTX exerts a powerful effect on donor T-cell proliferation and thereby inhibits GvHD.
Two common nonsynonymous MTHFR polymorphisms have been previously reported: one, a cytosine to thymine base substitution at position 677 (C-T) results in an alanine to valine amino-acid change at codon 222. 6 This polymorphism is situated at the binding site for flavin adenine dinucleotide (FAD), a required cofactor for MTHFR activity. The TT polymorphism at 677 has been shown to increase the dissociation of FAD from MTHFR. 7 The second polymorphism, an adenine to cytosine substitution at position 1298 (A-C), generates a glutamate to alanine amino-acid change at codon 429. 8 This polymorphism is located at the MTHFR protein regulatory domain, which binds the inhibitor S-adenosyl-L-methionine. 9 In vitro observations from lymphocyte extracts showed that 677 TT homozygous individuals have MTHFR activity 30-40% compared with that of wild type (CC) with 60% activity in heterozygotes. The 677 TT genotype has been linked to increased oral mucositis post HSCT in patients treated with MTX. 10, 11 In contrast, the 1298 C polymorphism has been associated with a decreased incidence of MTX toxicity in rheumatoid arthritis. 12 Polymorphisms at both 677 and 1298 have recently been shown to be associated with an increased risk of relapse in chronic myeloid leukemia after allogeneic HSCT transplant, 13 toxicity to MTX therapy in patients with acute leukemia, 14 vascular disease 6 and hyperhomocysteinemia contributing to chronic allograft nephropathy in renal transplant patients. 15 However, owing to the linkage disequilibrium between alleles at positions 677 and 1298, it is not possible to determine which polymorphism is functionally responsible for many of the above associations.
Given that the effectiveness of MTX may be influenced by MTHFR activity, we hypothesize that mutations at MTHFR 677 may be a marker for changes in the function of the enzyme resulting in variations in nucleotide synthesis, which in turn impacts on the ability of T cells to mount alloresponses. We therefore report on the association of a polymorphism at MTHFR 677 in both donor and recipients on GvHD outcome in HSCT patients.
Materials and methods

Study design and DNA collection
The study protocol was approved by the Human Ethics Committee of the Royal Melbourne Hospital. DNA samples were obtained from 193 adult HSCT recipients (178 caucasians, 15 noncaucasians) and their respective donors and MTHFR genotyped retrospectively. Allogeneic HSCT was undertaken for a variety of hematological conditions: AML (29% of patients), CML (21%), lymphomas (16%), ALL (14%), myelodysplasia and myeloproliferative disease (8%), plasma cell dyscrasias (5%), CLL (5%) and others (2%). The transplants were performed between June 1998 and May 2004 at a single, university-affiliated hospital and consisted of 140 related and 53 unrelated transplants. Patients having second transplants or T-cell-depleted transplants were excluded from the study as were those who died before day 14 after transplant and those with missing clinical data or without stored DNA. Two hundred Caucasian individuals from the Australian Bone Marrow Donor Registry were genotyped to provide normal population allele frequencies.
Clinical parameters
The first day of acute GvHD (aGvHD) was recorded. Severity was graded according to the International Bone Marrow Transplant Registry (IBMTR) severity index for skin, liver and gastrointestinal aGvHD. 16 Chronic graftversus-host disease (cGvHD) was evaluated using the original and the revised Seattle classification. 17 To calculate the number of post transplant days until GvHD, the first day of GvHD onset for either acute or chronic was recorded for each patient, irrespective of the grade or any further secondary GvHD manifestations. The number of days until systemic treatment were calculated in one of two ways: for those patients currently on immunosuppression, the first day when an increase in dose was required for GvHD treatment was used whereas for those patients not on immunosuppression, the day of resumption of systemic treatment was used. Systemic treatment consisted of the use of at least one of prednisolone, cyclosporine, tacrolimus, mycophenolate or extracorporeal photopheresis. For GvHD-associated outcomes, patients who died within 30 days post transplant were removed from the study.
Conditioning regimen
A total of 187 of the 193 patients (96.9%) received one of the following: cyclophosphamide and busulfan, cyclophosphamide and total body irradiation (TBI), fludarabine and melphalan, fludarabine and cyclophosphamide. The conditioning regimens are summarized in Table 1 .
GvHD prophylaxis
Methotrexate was administered to all patients based on a protocol of 15 mg/m 2 at day 1, and 10 mg/m 2 on days 3, 6 and 11 after transplant. At physician discretion, MTX doses were reduced owing to severe mucositis or hepatic dysfunction in 52 patients (33 related donor recipients, 19 unrelated donor recipients). Folinic acid rescue was an additional optional treatment in these circumstances. Continuous infusion of intravenous cyclosporine (3 mg/ kg) was administered to all patients starting on the day before transplantation with dose adjustments for toxicity. A total of 57 patients received prednisolone, administered after day 14 until day 100 post transplant following the protocol described by Ruutu et al.
18
Genotyping
The polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) method described by Kumagai et al. 19 was used to detect the MTHFR C677T single nucleotide polymorphism (SNP). Genotypes on eight representative samples covering all three genotypes were confirmed by sequencing using the C677T antisense primer (3730 Applied Biosystems DNA analyzer). Sequence data were analyzed using SeqScape s and compared to an MTHFR reference sequence. Unambiguous genotyping was possible for 187 HSCT recipients and 181 donors, which comprise the study group.
Statistical analysis
Event time distributions for the clinical outcomes were estimated using Kaplan-Meier incidence curves. Log-rank tests were used to evaluate differences in risk of an event occurring in comparison to the expected risk. Each predictor variable was examined by means of univariate analysis and those with a P-value o0.05 were considered statistically significant. P-values measuring differences between genotypes were calculated in univariate and multivariate analysis comparatively as one genotype versus the remaining two. All significant predictor variables, and those with Po0.25 were included in the initial Cox regression model by means of manual stepwise regression.
Demographic variables included age, weight, disease and sex of recipient and donor. Treatment variables included matching status, conditioning regimen, use of prophylactic corticosteroids, parenteral chemotherapy within 3 months of transplant, total MTX dose over 11 days (milligram per kilogram of body weight), folinic acid rescue use, related versus unrelated transplants, year of transplant, nonmyeloablative allogeneic transplant versus myeloablative transplant, bone marrow versus peripheral blood, neutrophil recovery day, HLA mismatching and risk status of the disease: standard or advanced. Data were analyzed using STATA 8.0 software.
Results
Patient demographics and transplant variables
Patient demographics and transplant variables are shown in Table 1 . All 193 patients received at least one dose of MTX as GvHD prophylaxis. Fifty-two patients (27%) had MTX doses reduced or withheld as described previously.
MTHFR genotype frequencies MTHFR 677 frequencies for the patients, donors and the normal population are shown in Table 2 . The frequencies conform to those previously published. 9 There were no significant differences between allele or genotype frequencies in the donors or recipients compared with the normal population. Genotypes were in HardyWeinberg equilibrium in all three groups.
Clinical outcomes
Of the 193 study participants, four died before 30 days and were removed from the analysis. Grades I-IV aGvHD occurred in 85% (160) patients with median onset at day 37. Grades III/IV aGvHD occurred in 23% (43) of the patients and GvHD was treated with systemic immunosuppression in 74% (140) patients.
Frequency and time to onset of GvHD and MTHFR 677 genotypes
There was a decreased frequency of GvHD (both acute and chronic) in the patients with an MTHFR 677CT or TT and HLA-matched related donor (Figure 1) . At 1 year, 75% of patients with either a 677 CT or TT donor had experienced acute and/or chronic GvHD versus 91% in the patients with a wild-type 677 CC donor (Po0.01). There was no significant association between the donor MTHFR 677 genotypes and GvHD incidence in the unrelated transplants (P ¼ 0.21). Univariate analysis on related transplants showed that the time to the first manifestation of GvHD (including both acute and chronic) was significantly longer in patients whose donor had a 677 CT or TT genotype (P ¼ 0.005, hazard ratio, 0.58 (a hazard ratio o1.0 indicates protection against GvHD whereas a hazard ratio 41.0 indicates increased risk for GvHD); 95% confidence interval (CI), 0.40-0.85 (Figure 1) ). This association was confirmed by the multivariable model (P ¼ 0.001, hazard ratio, 0.52; 95 CI 0.35-0.78). When patients with grade 1 GvHD or the 33 patients receiving less than the full dose of MTX were removed from the analysis, this association remained statistically significant. Factors in the model that contributed significantly to GvHD were the use of bone marrow compared to peripheral blood stem cells (P ¼ 0.041, hazard ratio, 1.55; 95 CI 1.02-2.35), and the conditioning regimen of fludarabine with cyclophosphamide (P ¼ 0.004, hazard ratio, 0.44; 95 CI 0.25-0.77). There was no association between the time to GvHD and donor MTHFR 677 polymorphisms in the unrelated cohort. The distribution of pre-transplant variables indicates that there were no significant differences in these variables between the two donor genotype groups, which could possibly confound the observed association with GvHD and MTHFR genotype (Table 3) . Importantly, MTX dose and duration of treatment did not differ between the MTHFR genotype groups.
Recipient MTHFR 677 genotypes were not associated with the time to onset or incidence of GvHD (87.6% in the wild-type CC genotype versus 82.7% in the CT and TT genotype groups combined at 1 year, P ¼ 0.24, data not shown).
Systemic treatment for GvHD and MTHFR 677 genotypes
There was a decreased frequency of GvHD that required systemic treatment in the first year after transplant for patients with either a 677 CT or TT and HLA-matched related donor (Figure 2) . At 1 year, 64% of patients with a 677 CT or TT donor had experienced GvHD that required systemic treatment versus 86% in the patients with a wildtype 677 CC donor (Po0.004). There was no significant association between the donor MTHFR 677 genotypes and incidence of GvHD that required systemic treatment in the unrelated transplants (P ¼ 0.77). The time to first GvHD requiring systemic therapy occurred significantly later in patients receiving related transplants from donors with Other factors in this model that independently significantly affected the time of onset of systemic treatment were the use of prophylactic corticosteroids (P ¼ 0.004, hazard ratio, 0.50; 95 CI 0.31-0.80), the conditioning regimen of fludarabine and cyclophosphamide (Po0.001, hazard ratio, 0.32; 95 CI 0.17-0.60) and a female recipient (P ¼ 0.029, hazard ratio, 1.63; 95 CI 1.05-2.52). Again, the MTHFR 677 association was not observed in the matched unrelated donor group (unrelated P ¼ 0.77). There was no association of incidence or time to systemic treatment for GvHD with recipient MTHFR 677 genotypes in either the related or unrelated donor groups.
Severity of acute GvHD in related transplants and MTHFR 677 genotypes
There was a weak association with donor MTHFR 677 CT or TT genotype and a less severe grade of aGvHD in related donor transplants (P ¼ 0.023, odds ratio 0.48; 95 CI 0.26-0.91; (data not shown). (The reference category for the ordinal regression was the absence of GvHD. Odds ratios should be interpreted as o1.0 being protective to higher grades of GvHD and 41.0 suggesting risk for higher grades of GvHD.) This association was confirmed by multivariate analysis (P ¼ 0.035, odds ratio, 0.51; CI 0.27-0.95). Other factors associated with severity of aGvHD were diagnosis of CML (P ¼ 0.032, odds ratio, 2.49; CI 1.08-5.74), the conditioning regimens of fludarabine with melphalan (P ¼ 0.017, odds ratio, 3.00; CI 1.22-7.37) and cyclophosphamide with TBI (P ¼ 0.017, odds ratio, 2.36; CI 1.17-4.77). The severity grade of aGvHD was not associated with recipient MTHFR 677 genotypes in either the related or unrelated donor transplants or with the donor MTHFR 677 genotypes in unrelated transplants. The severity of chronic GvHD did not appear to be associated with donor or recipient MTHFR 677 genotypes in related or unrelated transplants.
Discussion
The donor MTHFR 677 polymorphism appears to be associated with the incidence, timing and possibly severity of GvHD in patients transplanted with hematopoietic stem cells from an HLA-matched related donor, but not in patients transplanted with cells from an unrelated donor. The donor 677 CT or TT genotypes are associated with a later onset and decreased incidence of GvHD compared with donor wild-type CC genotype. At day 100, there is an approximately 20% decrease in the overall cumulative frequency of onset of GvHD in the combined TT and heterozygote CT group compared with the wild-type CC genotype group. This decreased incidence is still evident at 1 year post transplant. There is no evidence of a heterozygote effect, that is, there is no difference in the incidence and timing of GvHD between donor CT and TT genotypes. This may indicate a 'dominant' association of the T allele but the numbers in the TT group are too small to draw definitive conclusions. No associations were observed with recipient 677 genotypes.
We hypothesize that there are three possible explanations for our observations. Firstly, the levels of folate within the cell, which are critical for the production of purine and pyrimidine synthesis, can be influenced by the activity of MTHFR via its action of catalyzing the reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate as well as by DHFR activity. MTX, by inhibiting DHFR, can therefore strongly influence folate levels, and hence nucleotide synthesis. The effect of the MTHFR genotypes in the related donor transplants is first observed at approximately 15 days post transplant, 4 days after MTX is withdrawn from the majority of patients. This suggests that the genetic polymorphisms resulting in variable MTHFR function are not observed in the presence of MTX, which has a dominant inhibitory effect on nucleotide production owing to its folate depletion effects. An alternative view acknowledges that GvHD is rarely seen before day 15 in patients receiving any GvHD prophlylactic immunosuppression and that it would be impossible to see any effect during this early period in any event. From approximately day 15 onwards, the progression to GvHD is markedly different in the three donor MTHFR 677 genotype groups as is the overall incidence of GvHD at 1 year. The ability to utilize cellular 5,10-methylenetetrahydrofolate and replenish cellular tetrahydrofolate levels post-MTX treatment may provide donor T cells with an increased rate of nucleotide synthesis required for T-cell expansion, but the rate of this synthesis will be partially dependant on MTHFR genetic polymorphisms. Cells with the MTHFR wild-type 677 CC genotype have been shown to have an increased capacity to convert cellular 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate compared to cells carrying the 677 CT and TT genotypes. 9 The effect of the MTHFR polymorphism on GvHD may therefore be interpreted as a reflection of the increased production of nucleotides with the CC genotype in comparison to the CT and TT genotypes, resulting in an increasingly rapid proliferation of donor T cells manifesting clinically as GvHD. This hypothesis however is not supported by direct evidence either in vivo or in vitro that the wild-type 677 CC genotype is associated with increased nucleotide production compared with other genotypes.
Alternatively, the effect on GvHD may reflect negative selection of alloreactive cells in MTHFR 677 TT and to a lesser extent CT individuals. Quinlivan et al. 20 have demonstrated that the TT genotype is associated with increased thymidine production in female individuals on a low folate diet and this genotype has been shown to be associated with increased levels of lymphocytic cell growth in in vitro cultures compared with the wild-type CC genotype. 21 In addition, it has been shown in mice that the cytolytic effect of MTX is correlated with the degree of cellular proliferation. Cells in a rapid growth phase become purine depleted in the presence of MTX and apoptose. 22 It is possible therefore that there is increased depletion of T cells responding to alloantigenic differences in CT and TT individuals than individuals with the wild-type CC genotype. After withdrawal of MTX treatment, the survival advantage of T cells in CC individuals will be evident in an increased incidence of GvHD. If this hypothesis were correct, we would predict that in patients who do not receive MTX-based GvHD prophylaxis, a reverse effect would be observed, that is, the TT and CT genotypes would be associated with increased GvHD relative to the wild-type CC genotype.
Thirdly, plasma homocysteine may be contributing to GvHD reactions by promoting apoptosis of donor T cells. The MTHFR 677 TT genotype has been shown to be associated with elevated homocysteine levels in ovarian cancer patients treated with MTX. 23 Homocysteine has also been found to promote apoptosis of T cells in a dosedependent manner. 24 T cells capable of mounting a GvHD response may therefore be deleted or reduced in frequency in MTHFR TT individuals, thus explaining the decrease of GvHD observed in patients with this genotype. The same study however reported that homocysteine increased the production of type1 cytokines and activation of T cells, which is likely to result in more GvHD. The role of homocysteine in this context therefore requires further study.
Only one previous study of MTHFR polymorphism has attempted to correlate MTHFR genotypes with GvHD in HSCT recipients. The study by Pihusch et al., 25 which consisted of an equal number of related and unrelated donor HSCTs, examined MTHFR polymorphisms in recipients and donors and reported no effect of recipient MTHFR genotype on the incidence of GvHD. No analysis of donor genotypes appears to have been performed. We interpret our observation that these associations only occur in the related donor cohort as reflecting the fact that there are multiple HLA and non-HLA minor antigen differences in the unrelated transplants even in donors who are classified as 'matched'. 26 For example, nearly all unrelated transplants have some level of incompatibility at HLA-DP, which is known to increase the incidence of GvHD. 27 Likewise, related donor/recipient pairs who are fully HLA matched will, by virtue of their relatedness, be less mismatched for multiple minor non-HLA differences. Any subtle effects of enzyme polymorphisms on GvHD incidence therefore are more likely to be seen in patients with a lower background of antigenic differences that are known to cause GvHD. However, it is also possible that the lack of association in the unrelated donor cohort reflects the relatively small number of patients in this group compared with the related donor group. This lack of association requires confirmation in a larger group of patients.
The current findings have a potential role in determining treatment in individual patients and could assist in donor selection where more than one HLA-matched related donor is available. With the successful identification of critical SNPs in MTHFR contributing toward clinical outcome, further examination of polymorphisms in other key folate cycle enzymes such as the reduced folate carrier, folyl-gpolyl glutamate synthetase, thymidylate synthase and DHFR will be required to establish whether polymorphism in these genes also contributes to increased risk of GvHD.
Our future work will focus on these polymorphisms and whether the effects shown in the present study are observed in patients who have not received MTX.
